Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

In a breakthrough for cancer care in Nigeria, Biologix Laboratories limited, a wholly owned subsidiary of Biologix Support ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Survival rates also are lower for Black versus White people across various cancer types and categories of urbanicity.

A multicentre study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...

A year after the FDA approved the use of AngioDynamics' NanoKnife device for prostate cancer treatment, the magazine lists it ...

With D'Angelo's passing at 51 and a number of relatively young Black male stars dying from cancer and heart disease, it’s ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...